ARTICLE | Clinical News
Contusugene ladenovec regulatory update
August 10, 2009 7:00 AM UTC
EMEA said Introgen withdrew an MAA for Contusugene ladenovec to treat squamous cell carcinoma of the head and neck (SCCHN). According to the agency, Introgen withdrew the application based on its "dif...